Recombinant aggrecan variants having specifically modified CS chains and their regulation of axonal regeneration

Inhibition of chondroitin sulfate proteoglycans (CSPGs) produced by the glial scar represents one of th emajor challeges for regeneration and repair following spinal code surgery. The long-term goal of this study is to identify the mechanism(s) of CSPG-induced inhibition following nervous system injury and employ this knowledge for clinical application.